Us

Pic:getty/andrewbrookes

Biogen releases long-term Aduhelm data

By Rachel Arthur

Biogen has announced new Phase 3 data showing that, after nearly 2.5 years of treatment, Aduhelm continued to reduce two key Alzheimer’s disease pathologies.